Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.41 |
| ▸ | JAK3 | P52333 | 5/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | TEC | P42680 | 1/20 | 0.35 |
| ▸ | TXK | P42681 | 1/20 | 0.35 |
| ▸ | BMX | P51813 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002026 | 0.90 | JAK2 (0.42) | JAK2JAK3PIK3CAMTORPIK3CG | |
| SCHEMBL19836024 | 0.90 | JAK2 (0.42) | JAK2JAK3PIK3CAMTORPIK3CG | |
| SCHEMBL18996824 | 0.89 | BTK (0.42) | BTKTECTXKBMX | |
| SCHEMBL18996828 | 0.88 | BTK (0.47) | BTKTECTXKBMX | |
| SCHEMBL19836438 | 0.85 | JAK2 (0.37) | JAK2JAK3JAK1BTKTEC | |
| SCHEMBL19001728 | 0.83 | BTK (0.47) | JAK2JAK3GPR119TNK2BTK | |
| SCHEMBL19002024 | 0.82 | BTK (0.48) | JAK2JAK3BTKTECTXK | |
| SCHEMBL19002028 | 0.81 | BTK (0.45) | JAK2JAK3BTKTECTXK | |
| SCHEMBL19002012 | 0.81 | BTK (0.51) | BTKTECTXKBMX | |
| SCHEMBL19001730 | 0.81 | BTK (0.51) | BTKTECTXKBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055843-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20190092759-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-03-28 | — | — | US | disclosed |
| US-20180222893-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-08-09 | — | — | US | disclosed |
| US-9975882-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| US-9815822-B2 | — | — | 2017-11-14 | — | — | US | disclosed |
| US-20170174663-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222893-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | JAK2 17/4885JAK3 66/4885PIK3CA 33/4885 |
| US-20200055843-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | JAK2 17/4885JAK3 66/4885PIK3CA 33/4885 |
| US-20170174663-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | JAK2 17/4885JAK3 66/4885PIK3CA 33/4885 |
| US-20190092759-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | JAK2 17/4885JAK3 66/4885PIK3CA 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.